

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 0 786 256 A2**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
30.07.1997 Bulletin 1997/31

(51) Int Cl.<sup>8</sup>: **A61K 38/22**(21) Application number: **97300301.5**(22) Date of filing: **17.01.1997**

(84) Designated Contracting States:  
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL  
PT SE**  
Designated Extension States:  
**AL LT LV RO SI**

(30) Priority: **19.01.1996 US 10244**  
**07.02.1996 GB 9602406**

(71) Applicant: **ELI LILLY AND COMPANY**  
**Indianapolis, Indiana 46285 (US)**

(72) Inventors:  
• **Beale, John Michael**  
**Indianapolis, Indiana 46278-1853 (US)**

- **Dodd, Steven Witt**  
**Indianapolis, Indiana 46254 (US)**
- **Millican, Rohn Lee, Jr.**  
**Indianapolis, Indiana 46254 (US)**
- **Pekar, Allen Howard**  
**Indianapolis, Indiana 46220 (US)**

(74) Representative: **Hudson, Christopher Mark et al**  
**Lilly Industries Limited**  
**European Patent Operations**  
**Erl Wood Manor**  
**Windlesham Surrey GU20 6PH (GB)**

Remarks:

The applicant has subsequently filed a sequence listing and declared, that it includes no new matter.

(54) **Obesity protein formulations**

(57) The present invention discloses a soluble parenteral formulation, comprising an obesity protein analog and a preservative, said formulation having a low

ionic strength. The low ionic strength allows the preparation of a commercially viable multi-use pharmaceutical product.

**BEST AVAILABLE COPY**